135 related articles for article (PubMed ID: 10434891)
1. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma.
Grover R; Chana J; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1999 Mar; 52(2):122-6. PubMed ID: 10434891
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of c-myc oncogene expression in melanomas of the scalp.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Br J Plast Surg; 1998 Apr; 51(3):191-4. PubMed ID: 9664877
[TBL] [Abstract][Full Text] [Related]
3. Use of oncogene expression as an independent prognostic marker for primary melanoma.
Grover R; Pacifico MD; Wilson GD; Sanders R
Ann Plast Surg; 2003 Feb; 50(2):183-7. PubMed ID: 12567057
[TBL] [Abstract][Full Text] [Related]
4. A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma.
Ramsden AJ; Grover R; Chana J; Tulley P; Sanders R; Wilson GD
J Plast Reconstr Aesthet Surg; 2007; 60(6):626-30. PubMed ID: 17485049
[TBL] [Abstract][Full Text] [Related]
5. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1998 Jan; 85(1):46-51. PubMed ID: 9462382
[TBL] [Abstract][Full Text] [Related]
6. An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Br J Plast Surg; 2000 Jan; 53(1):46-50. PubMed ID: 10657449
[TBL] [Abstract][Full Text] [Related]
7. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
[TBL] [Abstract][Full Text] [Related]
8. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
10. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes.
Kalogeraki A; Garbagnati F; Darivianaki K; Delides GS; Santinami M; Stathopoulos EN; Zoras O
Anticancer Res; 2006; 26(5A):3551-4. PubMed ID: 17094481
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of oncogene expression in subungual melanoma.
Grover R; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1997 Jan; 50(1):15-9. PubMed ID: 9038509
[TBL] [Abstract][Full Text] [Related]
12. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
[TBL] [Abstract][Full Text] [Related]
13. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
14. Long term follow-up of c-myc, p53 and proliferation measurements in malignant melanoma.
Ross DA; Laing JH; Sanders R; Wilson GD
Eur J Surg Oncol; 2006 Feb; 32(1):80-4. PubMed ID: 16256294
[TBL] [Abstract][Full Text] [Related]
15. Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis.
Kageshita T; Kuriya N; Ono T; Horikoshi T; Takahashi M; Wong GY; Ferrone S
Cancer Res; 1993 Jun; 53(12):2830-3. PubMed ID: 8504426
[TBL] [Abstract][Full Text] [Related]
16. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy.
Pearl RA; Pacifico MD; Richman PI; Wilson GD; Grover R
J Plast Reconstr Aesthet Surg; 2008; 61(3):265-71. PubMed ID: 17569608
[TBL] [Abstract][Full Text] [Related]
17. Acral lentiginous melanoma: histopathological prognostic features of 121 cases.
Phan A; Touzet S; Dalle S; Ronger-Savlé S; Balme B; Thomas L
Br J Dermatol; 2007 Aug; 157(2):311-8. PubMed ID: 17596173
[TBL] [Abstract][Full Text] [Related]
18. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma.
Thies A; Schachner M; Berger J; Moll I; Schulze HJ; Brunner G; Schumacher U
J Pathol; 2004 Aug; 203(4):933-9. PubMed ID: 15258996
[TBL] [Abstract][Full Text] [Related]
19. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors.
Massi D; Borgognoni L; Franchi A; Martini L; Reali UM; Santucci M
Melanoma Res; 2000 Apr; 10(2):153-64. PubMed ID: 10803716
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]